Metsera and Maze Therapeutics Set for Nasdaq Debut Amid Surge in Healthcare IPOs

Intelligent Finance APP learned that Metsera (MTSR.US) and Maze Therapeutics (MAZE.US), two pharmaceutical companies, announced the pricing of their initial public offerings (IPOs) on Thursday. According to a statement, Metsera priced its IPO at $18 per share (above the previously announced IPO price range of $15-$17), and the company will sell 15.3 million shares to raise $275 million. Meanwhile, Maze Therapeutics priced its IPO at $16 per share (the midpoint of the previously announced IPO price range), and the company will sell 8.75 million shares to raise $140 million. The two companies will collectively raise $415 million.

Data shows that Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral medications for the treatment of obesity and related conditions. The company has $187.6 million in cash and cash equivalents. Its investors include a subsidiary of ARCH Venture Partners, Population Health Partners, Fidelity Investments, Mubadala Capital, and Google Ventures. The company's shares are set to begin trading on Nasdaq on Friday at Eastern Time.

Maze Therapeutics Focuses on Developing Drugs for Kidney, Heart, and Metabolic Diseases. Data shows that the company holds $149.6 million in cash and cash equivalents. The largest shareholder of the company is a subsidiary of Third Rock Ventures, with other investors including a subsidiary of ARCH Venture Partners, among others. The company’s shares will also begin trading on the Nasdaq under the U.S. Eastern Time on Friday.

In January, Beta Bionics (BBNX.US) conducted a $204 million IPO on Wednesday, and Ascentage Pharma issued $126 million in American Depository Shares on January 23. Data compiled by Bloomberg shows that in January this year, six listed companies in the U.S. healthcare industry raised more than $750 million, marking the busiest IPO month for the U.S. medical sector since October last year.